Odling av stamceller på specialdesignad nanofiberbaser matris för tillverkning av extracellulära vesiklar
Reference number | |
Coordinator | Cellevate AB |
Funding from Vinnova | SEK 4 963 863 |
Project duration | February 2022 - January 2025 |
Status | Ongoing |
Venture | Next-Generation Biologics 5 |
Call | New and improved biological drugs in healthcare |
Purpose and goal
Extracellular vesicles (EVs) have revolutionary potential as a novel treatment for numerous diseases including Myocardial Infarction, stroke, wound healing, and as a delivery vector for gene therapy. However, the field is stymied by a lack of established production methods. This project aims to alleviate these issues and generate a feasible GMP accepted culturing concept for stem cells for production of high quality EVs
Expected effects and result
If we manage to culture HSCs and MSCs in larger quantities with maintained regenerative potential, this would enable several EV-based academic and industrial entities to utilize the technique and enter clinical trials with much lower costs with a very promising cell source for their EVs. This could have a vast impact on both the industry as a whole as well as a society when diseases that previously were untreatable could be treated.
Planned approach and implementation
** Denna text är maskinöversatt ** This project is based on the concept that Karolinska Instituetet first analyzes the extracellular environment of hematopoietic and mesenchymal stem cells using advanced transcriptomic methods. Stem cells are provided by Karolinska Universitetssjukhuset. Then a synthetic extracellular matrix is designed based on Cellevate´s proprietary nanotechnology based on the results to create a relevant environment for physiological culture / expansion of stem cells in the goal of producing large amounts of regenerative extracellular vesicles.